2019 World Molecular Imaging Conference Poster
This study is the Company's first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion's Magsense™ technology, which provide…
HER2 Nanoparticle Safety and Specificity Data Presented at AACR 2019
Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster "HER2 Functionalized Nanoparticles Are Safe…
MR Imaging Market Coming Into Focus
In our September newsletter we announced that researchers at the University of Sydney had received an industry collaboration grant to investigate the use of…
MagSense™ Pre-Clinical Study Presented at 2018 SABCS
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…
MagSense Technology Animation
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense™…
Perspectives on X-Ray Imaging
This article represents the viewpoint of management. When MagSense technology reaches the clinic, it will join a distinguished pantheon of time-honored cancer…
MagSense™ Technology at ASCO 2018 Annual Meeting
The ASCO 2018 Annual Meeting abstract, "Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic…
MagSense Technology Leading a Broad Trend in Cancer Medicine
This article represents the viewpoint of management. MagSense™ technology is taking a leading position amidst a broad trend in cancer medicine toward finding…
MagSense™ Pre-Clinical Safety Data from AACR 2018
Pre-clinical data on Imagion Biosystems' MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro…
Imagion Biosystems Stock ASX:IBX Highlighted
Citing increasing demand from doctors to assess diseases close up, the Australian investment news service Stockhead has included Imagion Biosystems (ASX:IBX)…